The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia

Biological Psychiatry

Volumn 49, Issue 1, 2001, Pages 39-46

  Bertolino, A ^a   Callicott, J H ^a   Mattay, V S ^a   Weidenhammer, K M ^a   Rakow, R ^a   Egan, M F ^a   Weinberger, D R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Atypical antipsychotics; Dorsolateral prefrontal cortex; N acetylaspartate; Schizophrenia; Typical antipsychotics

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; MESORIDAZINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CELL FUNCTION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; MORPHOMETRICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BRAIN; BRAIN CHEMISTRY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 0035062495     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00997-5     Document Type: Article

References (66)

1. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
2. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations
3. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics
4. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
5. The relationship between dorsolateral prefrontal neuronal n-acetylaspartate and evoked release of striatal dopamine in schizophrenia
6. Regionally specific neuronal pathology in untreated patients with schizophrenia: A proton magnetic resonance spectroscopic imaging study
7. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia
8. A specific relationship between prefrontal neuronal n-acetylaspartate and activation of the working memory cortical network in schizophrenia
9. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia
10. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging
11. A specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
12. Postpubertal emergence of prefrontal neuronal deficits and altered dopaminergic behaviors in rats with neonatal hippocampal lesions
13. Proton magnetic resonance spectroscopic imaging in monkeys with mesial temporo-limbic lesions
14. The Psychiatric Symptom Assessment Scale (PSAS)
15. Frontal lobe of children with schizophrenia spectrum disorders: A proton magnetic resonance spectroscopic study
16. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia
17. 1H magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical neurodevelopmental and cognitive correlates
18. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited
19. Hippocampal N-acetylaspartate in unaffected siblings of patients with schizophrenia: A possible intermediate phenotype
20. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia
21. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging
22. N-Acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction
23. Decreased left frontal lobe N-acetylaspartate in schizophrenia
24. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy
25. Chemical pathology of acute demyelinating lesions and its correlations with disability
26. Regionally specific effects of atypical antipsychotics drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action
27. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons
28. Multisection proton MR spectroscopic imaging of the brain
29. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
30. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain
31. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain
32. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
33. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
34. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia
35. Working memory dysfunction in schizophrenia
36. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect
37. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol
38. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging
39. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum
40. Synaptic plasticity in the rat striatum following chronic haloperidol treatment
41. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia
42. Antipsychotic drug effects on glutamatergic activity
43. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo
44. Proton magnetic resonance spectroscopy: An in vivo method of estimating hippocampal neuronal depletion in schizophrenia
45. The mechanism of action of novel antipsychotic drugs
46. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography
47. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain
48. MRS metabolic markers of seizures and seizure-induced neuronal damage
49. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia: A pilot study
50. The influence of insulin hypoglycaemic coma, repeated electroshocks, and chlorpromazine or beta-phenylisopropylmethylamine administration on the free amino acids in the brain
51. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis
52. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
53. Enhancement of N-methyl-D-aspartate (NMDA) immunoreactivity in residual dendritic spines in the caudate-putamen nucleus after chronic haloperidol administration
54. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex
55. Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats
56. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
57. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients
58. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging
59. Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia
60. Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex
61. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
62. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy
63. Cell biology of the hippocampal formation in schizophrenia
64. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: A search for common ground
65. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
66. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls